CellCept 250 mg capsules
Sponsors
Centre Hospitalier Universitaire De Nantes, Eledon Pharmaceuticals Inc., Universitair Medisch Centrum Groningen, Universitair Medisch Centrum Groningen, Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron, Centre Hospitalier Universitaire De Limoges
Conditions
COVID-19Herpes ZosterPrevention viral infection (BKV) poliamavirus after kidney trasplantationProphylaxis of Renal Allograft RejectionRenal Transplantationacute myeloid leukemiaimpaired immunitykidney transplant
Phase 2
BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
Active, not recruitingCTIS2023-503336-41-00
Start: 2023-11-29Target: 101Updated: 2025-07-22
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(siplizumab) Compared to Anti-Thymocyte Globulin (rATG), as Induction Therapy in de novo Renal Transplant Recipients
CompletedCTIS2023-507895-36-00
Start: 2021-06-06End: 2024-12-11Target: 33Updated: 2024-08-02
Immunosuppression regimen reduction in kidney transplantation recipients admitted to the intensive care unit in the setting of septic shock and/or acute respiratory failure: an open multicentric randomized phase IV study
Not yet recruitingCTIS2024-518493-14-00
Target: 212Updated: 2025-11-19
Phase 3
FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busulfan versus fludarabine/busulfan) in adults with acute myeloid leukemia and eligible to allogeneic stem cell transplantation: a SFGM-TC study
RecruitingCTIS2022-502019-12-00
Start: 2023-09-14Target: 302Updated: 2024-11-29
Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients
CompletedCTIS2023-503894-39-00
Start: 2023-08-22End: 2024-02-27Target: 110Updated: 2023-10-10
Phase 4
Evaluation and promotion of specific adaptative immunity against polyomavirus (BKV) to prevent viral infection after kidney transplantation (BK-VAX project)
Not yet recruitingCTIS2023-504309-35-00
Target: 70Updated: 2023-06-15
Evaluation of the benefits of Administering immunosuppressive drugs as Single daily doses over the first Year after liver transplantation
RecruitingCTIS2023-506601-19-00
Start: 2025-04-15Target: 200Updated: 2025-10-07